Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Exp Clin Cancer Res ; 31: 57, 2012 Jun 15.
Article in English | MEDLINE | ID: mdl-22704648

ABSTRACT

The purpose of the current study was to determine whether a tropical ginger derived compound 1'-acetoxychavicol acetate (ACA), suppresses skin tumor promotion in K5.Stat3C mice. In a two-week study in which wild-type (WT) and K5.Stat3C mice were co-treated with either vehicle, ACA, galanga extract, or fluocinolone acetonide (FA) and tetradecanoyl phorbol acetate (TPA), only the galanga extract and FA suppressed TPA-induced skin hyperproliferation and wet weight. None of these agents were effective at suppressing p-Tyr705Stat3 expression. However, ACA and FA showed promising inhibitory effects against skin tumorigenesis in K5.Stat3C mice. ACA also suppressed phospho-p65 NF-κB activation, suggesting a potential mechanism for its action.


Subject(s)
Benzyl Alcohols/pharmacology , Cell Transformation, Neoplastic/drug effects , STAT3 Transcription Factor , Skin Neoplasms , 9,10-Dimethyl-1,2-benzanthracene/toxicity , Alpinia/chemistry , Animals , Cell Proliferation/drug effects , Cell Survival/drug effects , Fluocinolone Acetonide/pharmacology , Zingiber officinale/chemistry , Humans , Mice , Mice, Transgenic , NF-kappa B/antagonists & inhibitors , NF-kappa B/metabolism , Plant Extracts/chemistry , Plant Extracts/pharmacology , STAT3 Transcription Factor/genetics , STAT3 Transcription Factor/metabolism , Skin Neoplasms/chemically induced , Skin Neoplasms/drug therapy , Skin Neoplasms/pathology , Tetradecanoylphorbol Acetate/pharmacology
2.
Cancer Lett ; 312(1): 82-90, 2011 Dec 15.
Article in English | MEDLINE | ID: mdl-21893382

ABSTRACT

Clearly new breast cancer models are necessary in developing novel therapies. To address this challenge, we examined mammary tumor formation in the Syrian hamster using the chemical carcinogen N-methyl-N-nitrosourea (MNU). A single 50mg/kg intraperitoneal dose of MNU resulted in a 60% incidence of premalignant mammary lesions, and a 20% incidence of mammary adenocarcinomas. Two cell lines, HMAM4A and HMAM4B, were derived from one of the primary mammary tumors induced by MNU. The morphology of the primary tumor was similar to a high-grade poorly differentiated adenocarcinoma in human breast cancer. The primary tumor stained positively for both HER-2/neu and pancytokeratin, and negatively for both cytokeratin 5/6 and p63. When the HMAM4B cell line was implanted subcutaneously into syngeneic female hamsters, tumors grew at a take rate of 50%. A tumor derived from HMAM4B cells implanted into a syngeneic hamster was further propagated in vitro as a stable cell line HMAM5. The HMAM5 cells grew in female syngeneic hamsters with a 70% take rate of tumor formation. These cells proliferate in vitro, form colonies in soft agar, and are aneuploid with a modal chromosomal number of 74 (the normal chromosome number for Syrian hamster is 44). To determine responsiveness to the estrogen receptor (ER), a cell proliferation assay was examined using increasing concentrations of tamoxifen. Both HMAM5 and human MCF-7 (ER positive) cells showed a similar decrease at 24h. However, MDA-MB-231 (ER negative) cells were relatively insensitive to any decrease in proliferation from tamoxifen treatment. These results suggest that the HMAM5 cell line was likely derived from a luminal B subtype of mammary tumor. These results also represent characterization of the first mammary tumor cell line available from the Syrian hamster. The HMAM5 cell line is likely to be useful as an immunocompetent model for human breast cancer in developing novel therapies.


Subject(s)
Adenocarcinoma/pathology , Cell Line, Tumor , Disease Models, Animal , Mammary Neoplasms, Experimental/pathology , Methylnitrosourea , Adenocarcinoma/chemically induced , Animals , Carcinogens , Cricetinae , Female , Mammary Neoplasms, Experimental/chemically induced , Mesocricetus
SELECTION OF CITATIONS
SEARCH DETAIL
...